FDA Approves First Adjuvanted, Cell-Based Influenza Vaccine For Patients Six Months And Older In Event Of Pandemic

HCPlive (11/23, Walter) reports the Food and Drug Administration “has approved a multi-dose vial (MDV) platform for Influenza A(H5N1) Monovalent Vaccine, Adjuvanted (AUDENZ) for patients 6 months and older against influenza A(H5N1) in the event of a pande...